Neuroprotection in ischemic/hypoxic disorders: from the preclinical to the clinical testing.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002154:Calpain / Q000378:metabolism; D020169:Caspases / Q000378:metabolism; D016923:Cell Death; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D017781:Genes, Immediate-Early / Q000235:genetics; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000378:metabolism; D014748:Vinca Alkaloids / Q000627:therapeutic use
D016207:Cytokines; D006360:Heat-Shock Proteins; D018696:Neuroprotective Agents; D014748:Vinca Alkaloids; D009569:Nitric Oxide; C013983:vinpocetine; D002154:Calpain; D020169:Caspases; D002118:Calcium